MX2023005387A - Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a. - Google Patents

Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.

Info

Publication number
MX2023005387A
MX2023005387A MX2023005387A MX2023005387A MX2023005387A MX 2023005387 A MX2023005387 A MX 2023005387A MX 2023005387 A MX2023005387 A MX 2023005387A MX 2023005387 A MX2023005387 A MX 2023005387A MX 2023005387 A MX2023005387 A MX 2023005387A
Authority
MX
Mexico
Prior art keywords
degrees
sup
compound
cukî
radiation
Prior art date
Application number
MX2023005387A
Other languages
English (en)
Inventor
Toshio Fujiwara
Joanna Bis
Kusalakumari Sukumar Senthil Kumar
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2023005387A publication Critical patent/MX2023005387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objeto principal de la presente invención es proporcionar nuevos cristales de (S)-N2-[1-(4-fluorofenil)etil]-4-(1-metil-1H-p irazol-4-il)-N6-(pirazin-2-il)piridina-2,6-diamina maleato (en lo sucesivo, referido como el "compuesto A"). Un cristal de Forma-I del compuesto A, que muestra picos de difracción en su espectro de difracción de polvo de rayos-X en al menos los siguientes ángulos de difracción 2?: 6.9 grados, 9.4 grados, 12.5 grados, 15.1 grados, 16.4 grados, 18.3 grados, 19.0 grados, 24.9 grados, 25.4 grados, 27.3 grados, y 27.7 grados, en donde espectro de difracción de polvo de rayos-X se obtiene al utilizar radiación Cu Ka (?=1.54Å). Un cristal de Forma-II del compuesto A, que muestra picos de difracción en su espectro de difracción de polvo de rayos-X en al menos los siguientes ángulos de difracción 2?: 6.9 grados, 9.2 grados, 12.4 grados, 14.8 grados, 16.5 grados, 18.1 grados, 18.5 grados, 19.8 grados, 23.6 grados, 24.9 grados, y 27.7 grados, en donde espectro de difracción de polvo de rayos-X se obtiene al utilizar radiación Cu Ka (?=1.54Å).
MX2023005387A 2017-09-28 2020-07-13 Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a. MX2023005387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017187297 2017-09-28

Publications (1)

Publication Number Publication Date
MX2023005387A true MX2023005387A (es) 2023-05-23

Family

ID=65901897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007177A MX2020007177A (es) 2017-09-28 2018-09-27 Cristales.
MX2023005387A MX2023005387A (es) 2017-09-28 2020-07-13 Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020007177A MX2020007177A (es) 2017-09-28 2018-09-27 Cristales.

Country Status (12)

Country Link
US (1) US11680055B2 (es)
EP (1) EP3689862A4 (es)
JP (2) JPWO2019065793A1 (es)
KR (2) KR20200060418A (es)
CN (2) CN111132971A (es)
AU (2) AU2018338857B2 (es)
BR (1) BR112020005847A2 (es)
CA (1) CA3076803A1 (es)
MX (2) MX2020007177A (es)
PH (1) PH12020550139A1 (es)
RU (1) RU2020114659A (es)
WO (1) WO2019065793A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022239068A1 (ja) * 2021-05-10 2022-11-17 日本新薬株式会社 サイトカインストーム抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394999B1 (en) 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
WO2012020787A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 悪性リンパ腫治療剤

Also Published As

Publication number Publication date
AU2018338857B2 (en) 2023-05-25
PH12020550139A1 (en) 2020-12-07
KR20230142814A (ko) 2023-10-11
EP3689862A1 (en) 2020-08-05
JPWO2019065793A1 (ja) 2020-10-22
BR112020005847A2 (pt) 2020-09-29
CA3076803A1 (en) 2019-04-04
WO2019065793A1 (ja) 2019-04-04
US20200223823A1 (en) 2020-07-16
KR20200060418A (ko) 2020-05-29
AU2018338857A1 (en) 2020-04-16
RU2020114659A (ru) 2021-10-28
JP2023105140A (ja) 2023-07-28
CN111132971A (zh) 2020-05-08
RU2020114659A3 (es) 2022-04-08
MX2020007177A (es) 2020-10-14
US11680055B2 (en) 2023-06-20
CN116874467A (zh) 2023-10-13
EP3689862A4 (en) 2021-01-27
AU2023203547A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CY1122893T1 (el) Κρυσταλλοι
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
PH12015502775A1 (en) Amino triazine derivative and pharmaceutical composition comprising the same
MX2022015558A (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida.
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
MX2023005387A (es) Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.
EA201590250A1 (ru) Производные карбамат/мочевины
MX2019004967A (es) Sales de derivado de indazol y cristales de las mismas.
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
PH12021550374A1 (en) Small molecule menin inhibitors
PH12020551841A1 (en) Stable pharmaceutical formulation
SG11201809127PA (en) Crystalline polymorph of 15b-hydroxy-osaterone acetate
MX2021014104A (es) Formas cristalinas de 5-bromo-2,6-di(1 h-pirazol-1-il)pirimidin-4- amina y nuevas sales.
CO6270221A2 (es) "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
MX2020007881A (es) Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3- carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopr opil)-amida.
EA201200764A1 (ru) Производные хиназолина
MX2020011070A (es) Formas cristalinas de un compuesto.
NO20083186L (no) Krystallform av vinfluninditartrat
EA201990196A1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6